New drug may help more patients get Life-Saving CAR-T therapy
NCT ID NCT06784726
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving the drug odronextamab before CAR-T cell therapy can help control aggressive large B-cell lymphomas that have returned or not responded to prior treatment. About 27 adults will receive odronextamab to slow disease progression and increase the chance they can successfully undergo leukapheresis and receive CAR-T therapy. The goal is to improve access to this potentially curative treatment for more patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
- Radiation boost may supercharge CAR T-Cell therapy against tough lymphoma
- New combo therapy aims to stop aggressive lymphoma relapse
- New combo approach aims to boost CAR-T success in tough lymphoma
- Triple-Target CAR T-Cells offer new hope for tough blood cancers